BioVista’s Artificial Intelligence Platform Boosts Drug Discovery

BioVista has eight ongoing projects that involve using its technology to provide discovery, repositioning, adverse event profiling, patient stratification and other services for partners…BioVista said partnering discussions are ongoing for BVA-201 and BVA-601, but the company has not yet determined how far into preclinical and possibly clinical studies it is willing to take its compounds before out-licensing them…BioVista started out predicting side effects, and such services are still a part of…

Read More…